A b cell depleting agent for the treatment of atherosclerosis or post myocardial infarction

New anti-atherogenic strategies based on B cell modulation, and suggest that patients currently treated with CD20 antibodies for other immune-mediated diseases might also benefit from a reduction of cardiovascular risk through limitation of atherosclerotic lesion development or inflammation. CD20-antibody-mediated depletion of mature B lymphocytes impeded monocyte mobilization, limited myocardial injury and improved heart function after acute MI in mice. Results in various animal models; Availability and safety of humanized monoclonal anti-CD20 antibodies in humans. (Zouggari Y. et al., Nat Med. 2013 Oct;19(10):1273-80; Ait-Oufella H. et al., J Exp Med. 2010 Aug 2;207(8):1579-87.)

Keywords: Atherosclerosis, B cell depleting agent, B cell, Anti-CD20 mAb, CD20, Antibody
Patent Application number: EP09305013.6
Zouggari Y. et al. Nat Med. 2013 Oct;19(10):1273-80; Ait-Oufella H. et al. J Exp Med. 2010 Aug 2;207(8):1579-87.

You might also be interested in